Ultragenyx Pharmaceutical Inc
RARE
查看详细走势图
19.850USD
+1.350+7.30%
收盘 03/25, 16:00（美东）报价延迟15分钟
576.88M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.30%
5天
-2.98%
1月
-13.36%
6月
-28.65%
今年开始到现在
-13.70%
1年
-48.69%
查看详细走势图
TradingKey Ultragenyx Pharmaceutical Inc股票评分
单位: USD 更新时间: 2026-03-25操作建议
Ultragenyx Pharmaceutical Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名57/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价51.32。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Ultragenyx Pharmaceutical Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Ultragenyx Pharmaceutical Inc亮点
亮点风险
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
业绩高增长
公司营业收入稳步增长，连续3年增长54.98%
估值高估
公司最新PE估值-3.40，处于3年历史高位
机构减仓
最新机构持股100.29M股，环比减少2.15%
肯·费雪持仓
明星投资者肯·费雪持仓，最新持仓市值198.70K
活跃度降低
近期活跃度降低，过去20天平均换手率0.41
分析师目标
根据
20
位分析师
买入
评级
51.316
目标均价
+153.16%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Ultragenyx Pharmaceutical Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Ultragenyx Pharmaceutical Inc简介
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
公司代码RARE
公司Ultragenyx Pharmaceutical Inc
CEOKakkis (Emil D)
网址https://www.ultragenyx.com/
相关品种
